Eylea® (Aflibercept)

DRUG2 trials

Sponsors

Bioeq GmbH, Alvotech Swiss AG

Conditions

Neovascular (Wet) AMDNeovascular Age-related Macular Degeneration

Phase 3

Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration

CompletedNCT04522167

Bioeq GmbHNeovascular Age-related Macular Degeneration

Start: 2020-07-21End: 2023-05-18Updated: 2025-11-13

Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)

CompletedNCT05155293

Alvotech Swiss AGNeovascular (Wet) AMD

Start: 2022-06-28End: 2024-09-23Updated: 2024-09-27

Related Papers

Randomised, double-masked trial to compare the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in patients with neovascular age-related macular degeneration.

2026-01-05

A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product aflibercept in participants with neovascular age-related macular degeneration

Expert Opinion on Biological Therapy2025-06-132 citations